The Use of Methylene Blue in Patients with Refractory Circulatory Shock

Authors

Richard Ragusa, University of LynchburgFollow

Specialty

Critical Care

Abstract

ABSTRACT

This review evaluates the efficacy of Methylene Blue (MB) in managing refractory circulatory shock, a condition where conventional therapies often prove insufficient. MB is now recognized for its ability to reverse the vasodilation effects of shock states, where it was previously only used for methemoglobinemia, Metformin toxicity, and anaphylaxis. Systematic research of medical databases identified studies assessing the cost-effectiveness, treatment efficacy, and effects on morbidity and mortality of MB. MB has been shown to improve outcomes by decreasing ICU and hospital stays, lowering mortality, and reducing the requirement for high-dose vasopressors, thereby minimizing associated complications. Despite promising results, small sample sizes and restricted scope of available studies underscore the necessity for further investigation prior to broad clinical integration. This review underscores MB’s potential to improve outcomes in refractory shock and supports its consideration as an adjunct therapy in critical care practice.

Keywords: Methylene Blue, Circulatory Shock, Critical Care, Intensive Care Unit, Vasopressors, Life Support

Recommended Citation

Ragusa R. The Use of Methylene Blue in Patients with Refractory Circulatory Shock. University of Lynchburg DMSc Doctoral Project Assignment Repository. 2025; 7(3).